Societal Impact of Pain Costs the EU up to 441 Billion Euros Annually
Pain causes a problem for individuals as well as a challenge for healthcare systems, economies and society: each year, approximately one in five Europeans or 20 percent of the adult population in Europe are affected by chronic pain. This includes 153 million people suffering migraine or other disabling headaches, 200 million musculoskeletal disorders and 100 million people experiencing other forms of chronic pain. The estimated direct and indirect healthcare costs for chronic pain disorders in European Member States vary between two and three percent of GDP across the EU. For 2016, this estimate would result in up to 441 billion Euros. Therefore, in advance of the Societal Impact of Pain symposium, experts in pain care call upon European and national policymakers to improve pain care policies and boost the productivity of the European workforce.
The European Union and its member states are confronted with substantial challenges. On the one hand, the need to increase productivity and prevent involuntary early retirement, on the other hand, to provide a social system that cares for an ageing population. In early 2017, the discussion in the European Parliament on the European Semester for economic policy coordination led to a resolution. In this resolution the European Parliament expressed its concern about the effects of demographic developments on public finances, pensions and healthcare systems and warns that the already foreseeable funding costs will have a significant impact.
Experts estimate that half of all citizens living in the EU at some point in their lives suffer from back pain. Approximately 15 percent of these citizens with back pain are on sick leave for over one month. Worldwide chronic pain conditions (in particular back pain) are by far the greatest cause of disability. Unsurprisingly chronic pain is one of the major reasons why people exit the labour market prematurely and it contributes significantly to disability retirement.
Aside from its effect on the workforce, chronic pain is one of the top causes of disability in every region of Europe and increases the risks of other health problems, social exclusion and poverty. Stigma and lack of public knowledge worsen the burden on patients and families by preventing people in pain from seeking treatment. Large health inequalities persist in the EU as many patients do not have access to adequate pain treatment.
Although pan-European data comparing the impact of pain on health care systems are lacking, we know that pain disorders are amongst the most prevalent, costly and disabling conditions in the workplace. Analysis focussing on the impact of pain on labour force participation, absence from work (absenteeism) and attending work while sick (presenteeism) have demonstrated that the experience of pain had a substantial negative association with labour force participation in Europe.
Due to the effects of pain on rates of absenteeism, reduced productivity and even the risk of employees leaving the labour market, social protection systems spend a large budget on pain related complaints. Data from the Labour Force Survey shows that over 2.3 million people in the UK report conditions or disabilities related to their back or neck as their main health problem. In 2013, low back pain was ranked highest of all injury-related disabilities and yielded the largest total number of “Years Lived with Disability” throughout England. With more than 500 million sick days per year in Europe, musculoskeletal pain causes almost 50 percent of all absences from work lasting at least three days in the EU and 60 percent of permanent work incapacity.
Healthy citizens, on the other side, reduce the strain on healthcare systems and boost economic growth by staying active for longer. Effective pain policies can positively impact the productivity and longevity of Europe’s labour force and delay early retirement.
Under the auspices of the 2017 Maltese Presidency of the Council of the EU the Societal Impact of Pain symposium from June 7–9, 2017 will bring together more than 300 participants representing healthcare professionals, pain advocacy groups, researchers and specialists in the field of pain as well as insurers and budget holders. The SIP platform aims to create structured EU-wide cooperation with lasting political impact, to find solutions that improve the lives of those with chronic pain, but also minimize the impact of pain on society.
- Ends -
About the SIP-Platform
The Societal Impact of Pain (SIP) is an international, multi-stakeholder platform created as a joint initiative of the European Pain Federation EFIC® and Grünenthal with the aim to:
- raise awareness of the relevance of the impact that pain has on our societies, health and economic systems
- exchange information and sharing best-practices across all Member States of the European Union
- develop and foster European-wide policy strategies for an improved pain management in Europe (Pain Policy).
Over 300 international and national pain advocacy groups, scientific organisations and authorities have endorsed the scientific aims of SIP symposia and meetings.
The scientific framework of the “Societal Impact of Pain” (SIP) platform is under the responsibility of the European Pain Federation EFIC ®. Cooperation partners for SIP 2017 are Pain Alliance Europe (PAE) and Active Citizenship Network (ACN). The SIP 2017 symposium is co-hosted by the Malta Health Network and the No Pain Foundation. The pharmaceutical company Grünenthal GmbH is responsible for funding and non-financial support (e.g. logistical support). In the past the scientific aims of the SIP symposia have been endorsed by over 300 international and national pain advocacy groups, scientific organisations and authorities.
References can be provided upon request
You can find more information at www.SIP-Platform.eu
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170519005141/en/
Contact information
Grayling for SIP
Sabrina Kieback
Sabrina.kieback@grayling.com
+49
(0)69 96 22 19 52)
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
A-CAP Announces Successful Divestiture of Standard de Liège SA and Immobilière du Standard de Liège SRL6.6.2025 23:32:00 EEST | Press release
Advantage Capital Holdings, LLC (“A-CAP” or “The Company”), a New York-based insurance and financial services company with over $12 billion in assets, today announced the successful divestiture of Standard de Liège SA (“Standard Liège” or the “Club”), one of Belgium's most historic soccer clubs, and Immobilière du Standard de Liège SRL, the corporate entity that owns the Club's stadium, Maurice Dufrasne Stadium, to a consortium of buyers led by Standard Liège Chief Executive Officer Giacomo Angelini. This transaction marks the end of 777 Partners’ legacy involvement with the Club and sets the stage for the Club’s future growth and success, both on and off the field. Benefits of the transaction include: Increased stability across the Club’s shareholder base, which clears the path for future investments, Operational clarity, establishing a unified direction that will allow both players and management to fully concentrate on on-field performance, ensuring that collective focus remains on
Populous Acquires Fentress Architects, Expanding Global Aviation Portfolio6.6.2025 21:00:00 EEST | Press release
Populous, the world-renowned design firm specializing in sport and entertainment venues, today announced the acquisition of Denver-based Fentress Architects, a global leader in iconic aviation projects and prominent public buildings, including convention centers, museums and government facilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606849000/en/ Los Angeles International Airport. Designed by Fentress Architects. This strategic acquisition unites two of the most respected names in architecture, combining Populous’ unparalleled expertise in designing memorable experiences with Fentress’ award-winning portfolio of aviation, civic and cultural landmarks. The acquisition significantly broadens the scope and scale of services that Populous can offer clients across the globe. Bruce Miller, Populous Global Chair and CEO, commented: “We are committed to expanding the breadth of our practice. Fentress Architects has lon
Vertex Presents New Data on Benefits of ALYFTREK ® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference6.6.2025 19:00:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy. During the conference, the Company presented data from a pooled analysis across CFTR modulators, including ALYFTREK, which demonstrate that reduction in sweat chloride (SwCl), and therefore greater restoration of CFTR function, is associated with improved outcomes in people with cystic fibrosis (CF). For all clinical outcomes in the study, SwCl levels below 60 mmol/L were associated with greater benefit
IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10 th Anniversary Year of NAHYCO ® Technology6.6.2025 17:00:00 EEST | Press release
IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the latest innovations and cutting-edge advancements in aesthetic procedures and treatments, staying at the forefront of this dynamic field. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603094257/en/ IBSA’s stand at IMCAS Asia 2025 As part of the congress, IBSA Derma will host a scientific symposium titled “The Future of Tissue Regeneration with NAHYCO® Technology. Feeling and Seeing the Results with Profhilo® Line” scheduled for Saturday, June 7, from 3:00 to 4:00 pm ICT in Room 1 - Level 2. Internationally renowned speakers – Dr. Lam Bee Lan and Prof. Ofir Artzi – will lead
HistoSonics Completes Enrollment in #HOPE4KIDNEY Trial Evaluating Non-Invasive Histotripsy to Treat Kidney Tumors6.6.2025 15:00:00 EEST | Press release
HistoSonics, Inc., the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, today announced the completion of patient enrollment in its pivotal #HOPE4KIDNEY trial. This prospective, multi-center, single-arm trial is designed to evaluate the safety and effectiveness of the Edison System in destroying kidney tissue by treating primary solid kidney tumors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606659747/en/ Edison Histotripsy System Procedure for Kidney Tumor Animation The trial enrolled patients with a single, non-metastatic solid kidney mass ≤3 cm, confirmed by imaging and biopsy. Subjects will be followed for five years post-procedure, with evaluations at multiple time points, including 14-day, 30-day, 90-day, 180-day, and annual assessments. The Edison System remains in investigational use for kidney applications and is not yet FDA-approved for this indication. Data from the #H
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom